At ASCO GU 2026, the group discussed results from KEYNOTE-B15, a phase III trial evaluating perioperative enfortumab vedotin plus pembrolizumab versus standard gemcitabine-cisplatin in muscle-invasive bladder cancer. The EV-pembrolizumab regimen significantly improved event-free survival, overall survival, and pathologic complete response rates, highlighting its potential to redefine perioperative treatment. They also emphasized the importance and limitations of pathologic complete response as a surrogate endpoint, particularly as the field continues to explore bladder preservation strategies.
Contributors:
Dr. Petros Grivas is a medical oncologist and professor at the University of Washington and Fred Hutchinson Cancer Center in Seattle.
Dr. Bradley McGregor is a medical oncologist at Dana-Farber in Boston.
Dr. Ashish Kamat is a urologic oncologist at MD Anderson in Houston, Texas and president of The International Bladder Cancer Group.
Dr. Sia Daneshmand is a professor of urology and oncology at the University of Southern California, Norris Comprehensive Cancer Center.
Dr. Matthew Galsky is a medical oncologist at the Icahn School of Medicine at Mount Sinai.
Dr. Guru Sonpavde is a medical oncologist and the Phase 1 new drug development program Director at the AdventHealth Cancer Institute in Orlando, Florida.
